AMAG Announces Financial Results For The Second Quarter And Six Months Ended June 30, 2012

A live webcast of the conference call and accompanying slides will be accessible through the Investors section of the Company’s website at www.amagpharma.com beginning at 8:00 a.m. ET. Following the conference call, the webcast replay will be available at approximately 10:00 a.m. ET and will be archived on the AMAG Pharmaceuticals, Inc. website until midnight August 26, 2012.

About Feraheme

In the United States, Feraheme® (ferumoxytol) Injection for Intravenous (IV) use is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients. Feraheme received marketing approval from the U.S. Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the U.S. shortly thereafter. Ferumoxytol received marketing approval in Canada in December 2011 and in the European Union in June 2012. For additional product information, please visit www.feraheme.com.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that manufactures and markets Feraheme® in the United States. For additional company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG Pharmaceuticals, Inc.

¹IMS Health DDD Data (in grams) through the period ending June 30, 2012.

AMAG Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(unaudited, amounts in thousands, except for per share data)
		Three Months Ended June 30,						Six Months Ended June 30,
			2012			2011			2012			2011
Revenues:
Product sales, net		$	14,420		$	13,081		$	28,128		$	24,103
License fee, collaboration and royalty revenues			16,592			2,321			18,364			4,684
Total revenues			31,012			15,402			46,492			28,787
Operating costs and expenses (1):
Cost of product sales			3,224			2,082			5,870			5,123
Research and development expenses			7,671			16,695			20,133			30,261
Selling, general and administrative expenses			15,101			16,826			28,282			36,460
Restructuring Expense			1,058			-			1,058			-
Total operating costs and expenses			27,054			35,603			55,343			71,844
Operating Income (Loss)			3,958			(20,201)			(8,851)			(43,057)
Interest and dividend income, net			338			452			731			1,012
Other income (expense)			(1,471)			(209)			(1,471)			(208)
Net income (loss) before income taxes			2,825			(19,958)			(9,591)			(42,253)
Income tax benefit			494			396			494			396
Net income (loss)		$	3,319		$	(19,562)		$	(9,097)		$	(41,857)
Net income (loss) per basic share:		$	0.16		$	(0.92)		$	(0.43)		$	(1.98)
Net income (loss) per diluted share:		$	0.15		$	(0.92)		$	(0.43)		$	(1.98)
Weighted average shares outstanding used to compute net income (loss) per share:
Basic			21,370			21,167			21,359			21,156
Diluted			21,649			21,167			21,359			21,156
(1) Stock-based compensation included in operating costs and expenses:
Cost of product sales		$	68		$	157		$	146		$	352
Research and development		$	525		$	639		$	947		$	1,281
Selling, general and administrative		$	984		$	1,825		$	2,169		$	5,463

AMAG Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(unaudited, amounts in thousands)
		June 30, 2012			December 31, 2011
Cash and cash equivalents		$	30,678		$	63,474
Short-term investments			176,571			148,703
Accounts receivable, net			5,778			5,932
Inventories			13,580			15,206
Receivable from collaboration			15,133			428
Other current assets			4,202			6,288
Total current assets			245,942			240,031
Net property, plant & equipment			7,831			9,206
Long-term investments			-			17,527
Other assets			460			460
Total assets		$	254,233		$	267,224
Accounts payable		$	3,757		$	3,732
Accrued expenses and other short-term liabilities			23,351			28,916
Deferred revenues			6,346			6,346
Total current liabilities			33,454			38,994
Deferred revenues			42,148			45,196
Other long-term liabilities			2,239			2,438
Total long-term liabilities			44,387			47,634
Total stockholders’ equity			176,392			180,596
Total liabilities and stockholders’ equity		$	254,233		$	267,224

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, our intention to divest our manufacturing facility and reduce our workforce by 45 positions, our expectation to submit a supplemental new drug application to the U.S. Food and Drug Administration by the end of 2012, our belief that we are ready to add additional products to our portfolio, and our belief that our recent initiatives will strengthen our business and lead to more predictable operating margins in future periods, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

« First ‹ Previous 1 2 3 4 5 Next › Last »